StreetInsider.com News Articles

Veru, Inc. (VERU) PT Lowered to $24 at Oppenheimer

Fri, 15 May 2026 07:48:23 -0400

Oppenheimer analyst Leland Gershell lowered the price target on Veru, Inc. (NASDAQ: VERU) to $24.00 (from $25.00) while maintaining a Outperform rating.

Form S-8 VERU INC.

Wed, 13 May 2026 09:20:00 -0400

si-local-file:///var/storage/secattach/20260513/26483058.html

Form S-8 VERU INC.

Wed, 13 May 2026 09:20:00 -0400

si-local-file:///var/storage/secattach/20260513/26483058.html

Form 10-Q VERU INC. For: Mar 31

Wed, 13 May 2026 09:10:00 -0400

si-local-file:///var/storage/secattach/20260513/26482958.html

Form 10-Q VERU INC. For: Mar 31

Wed, 13 May 2026 09:10:00 -0400

si-local-file:///var/storage/secattach/20260513/26482958.html

Form 8-K VERU INC. For: May 13

Wed, 13 May 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260513/26481438.html

Form 8-K VERU INC. For: May 13

Wed, 13 May 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260513/26481438.html

Veru, Inc. (VERU) Misses Q2 EPS by 13c

Wed, 13 May 2026 06:41:19 -0400

Veru, Inc. (NASDAQ: VERU) reported Q2 EPS of ($0.13).

For earnings history and earnings-related data on Veru, Inc. (VERU) click here.

Veru reports second quarter fiscal 2026 results and obesity trial update

Wed, 13 May 2026 06:30:28 -0400

Veru Inc. (NASDAQ: VERU) reported financial results for its fiscal 2026 second quarter ended March 31, 2026, showing reduced losses compared to the prior year period. The biopharmaceutical company also provided an update on its Phase 2b PLATEAU clinical trial evaluating enobosarm combined with semaglutide for obesity treatment.

For the second quarter, net loss decreased to $2.7 million, or $0.12 per share, compared to $7.9 million, or $0.54 per share, in the same period last year. Operating loss from continuing operations fell to $7.2 million from $8.1 million year-over-year.

Research and development expenses declined to $3.1 million from $3.9 million, while general

Veru reports second quarter fiscal 2026 results and obesity trial update

Wed, 13 May 2026 06:30:28 -0400

Research and development expenses declined to $3.1 million from $3.9 million, while general

Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Wed, 13 May 2026 06:30:00 -0400

--Phase 2b PLATEAU clinical study evaluating enobosarm + semaglutide is actively enrolling and on track for interim analysis first quarter calendar year 2027—

--Company to host conference call and webcast today at 8:00 a.m. ET—

MIAMI, FL, May 13, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced financial results for its fiscal 2026 second quarter ended March 31, 2026, and provided a corporate update.

"We are extremely pleased with the progress of

Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Wed, 13 May 2026 06:30:00 -0400

--Phase 2b PLATEAU clinical study evaluating enobosarm + semaglutide is actively enrolling and on track for interim analysis first quarter calendar year 2027—

--Company to host conference call and webcast today at 8:00 a.m. ET—

"We are extremely pleased with the progress of

Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Wed, 13 May 2026 06:30:00 -0400

--Phase 2b PLATEAU clinical study evaluating enobosarm + semaglutide is actively enrolling and on track for interim analysis first quarter calendar year 2027—

--Company to host conference call and webcast today at 8:00 a.m. ET—

"We are extremely pleased with the progress of

Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Wed, 13 May 2026 06:30:00 -0400

--Phase 2b PLATEAU clinical study evaluating enobosarm + semaglutide is actively enrolling and on track for interim analysis first quarter calendar year 2027—

--Company to host conference call and webcast today at 8:00 a.m. ET—

"We are extremely pleased with the progress of

Form 4 VERU INC. For: May 04 Filed by: STEINER MITCHELL SHUSTER

Wed, 06 May 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260506/26445408.html

Form 4 VERU INC. For: May 04 Filed by: STEINER MITCHELL SHUSTER

Wed, 06 May 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260506/26445408.html

Form 4 VERU INC. For: May 04 Filed by: Greco Michele

Wed, 06 May 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260506/26445196.html

Form 4 VERU INC. For: May 04 Filed by: Greco Michele

Wed, 06 May 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260506/26445196.html

Form 4 VERU INC. For: May 04 Filed by: Katzovitz Loren Mark

Wed, 06 May 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260506/26444992.html

Form 4 VERU INC. For: May 04 Filed by: Katzovitz Loren Mark

Wed, 06 May 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260506/26444992.html

Form 4 VERU INC. For: May 04 Filed by: Hyun Grace

Wed, 06 May 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260506/26444748.html

Form 4 VERU INC. For: May 04 Filed by: Hyun Grace

Wed, 06 May 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260506/26444748.html

Form 4 VERU INC. For: May 04 Filed by: Rankowitz Michael L

Wed, 06 May 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260506/26444307.html

Form 4 VERU INC. For: May 04 Filed by: Rankowitz Michael L

Wed, 06 May 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260506/26444307.html

Form 4 VERU INC. For: May 04 Filed by: Lu Lucy

Wed, 06 May 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260506/26443845.html